PharmaForce International's 2019 Oncology Studies benchmark key expenditures and organizational approaches of leading Oncology sales and marketing organizations around the globe. The United States is just one of five regions that PFI covers in the Oncology market.
READING, Pennsylvania, May 23, 2019 /PRNewswire/ -- PFI's newest U.S. Oncology benchmarking report is complete and available to be purchased this month. The report profiles 34 pharmaceutical and biotech companies, providing a detailed analysis of the leading Oncology franchises. This brand-new study includes key insights on the commercialization developments that are influencing the U.S. marketplaces for liquid and solid tumors.
The market trends captured within include:
Additional regions covered in PFI's Oncology reports that are available within the next month include India and Europe (France, Germany, Italy, Spain, and the United Kingdom). In addition, Oncology benchmarking studies for Japan and Latin America (Argentina, Brazil, Colombia, and Mexico) are anticipated to be available within the next quarter of this year.
Each company section of these reports will identify relevant and strategic developments along with up-to-date information on:
For more information on the reports mentioned above, please contact Joyce Wedemeyer at Joyce.Wedemeyer@strategicreports.com or by phone at 610-370-2906.
PharmaForce International (PFI) is a competitive intelligence firm with over two decades of experience in the pharmaceutical and biotech industries. PFI has become the market leader in commercial operations benchmarking and competitive intelligence. The globally focused company employs market place experts uniquely qualified to perform research required by clients in most major pharmaceutical markets around the world.
Additional Resources:
Logo - https://mma.prnewswire.com/media/467889/PharmaForce_International_Logo.jpg